Oertel WH - Search Results

1

[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.

Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. Antonini A, et al. Among authors: oertel wh. Neurology. 1994 Jul;44(7):1325-9. doi: 10.1212/wnl.44.7.1325. Neurology. 1994. PMID: 8035939

2

Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.

Schwarz J, Antonini A, Kraft E, Tatsch K, Vogl T, Kirsch CM, Leenders KL, Oertel WH. Schwarz J, et al. Among authors: oertel wh. Neurology. 1994 Jun;44(6):1079-82. doi: 10.1212/wnl.44.6.1079. Neurology. 1994. PMID: 8208404

3

T2 relaxation time in patients with Parkinson's disease.

Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M. Antonini A, et al. Among authors: oertel wh. Neurology. 1993 Apr;43(4):697-700. doi: 10.1212/wnl.43.4.697. Neurology. 1993. PMID: 8469325

4

Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.

Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Antonini A, et al. Among authors: oertel wh. Mov Disord. 1997 Jan;12(1):33-8. doi: 10.1002/mds.870120107. Mov Disord. 1997. PMID: 8990051

5

Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease.

Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Gasser T, et al. Among authors: oertel wh. Arch Neurol. 1992 Nov;49(11):1131-4. doi: 10.1001/archneur.1992.00530350045017. Arch Neurol. 1992. PMID: 1444878

6

Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease.

Oertel WH, Tatsch K, Schwarz J, Kraft E, Trenkwalder C, Scherer J, Weinzierl M, Vogl T, Kirsch CM. Oertel WH, et al. Ann Neurol. 1992 Dec;32(6):743-8. doi: 10.1002/ana.410320607. Ann Neurol. 1992. PMID: 1471864

7

123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.

Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH. Schwarz J, et al. Among authors: oertel wh. Neurology. 1992 Mar;42(3 Pt 1):556-61. doi: 10.1212/wnl.42.3.556. Neurology. 1992. PMID: 1549216

8

Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.

Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL. Schwarz J, et al. Among authors: oertel wh. Nucl Med Commun. 1994 Oct;15(10):806-13. doi: 10.1097/00006231-199410000-00006. Nucl Med Commun. 1994. PMID: 7838444 Clinical Trial.

9

IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.

Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch CM. Oertel WH, et al. Adv Neurol. 1993;60:519-24. Adv Neurol. 1993. PMID: 8420182

10

Parkinson's disease: clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions.

Leenders KL, Oertel WH. Leenders KL, et al. Among authors: oertel wh. Neural Plast. 2001;8(1-2):99-110. doi: 10.1155/NP.2001.99. Neural Plast. 2001. PMID: 11530892 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

649 results

Search Page

Filters